Cellogen Therapeutics Raises ₹20 Crore for CAR-T Therapy

Cellogen Therapeutics, an Indian biotechnology firm, has successfully closed a funding round totaling ₹20 crore (approximately $2.4 million). The investment was led by Kotak Alternate Asset Managers through its dedicated Kotak Life Sciences Fund I. This capital infusion signifies substantial backing for Cellogen's innovative approach to developing next-generation cell therapies aimed at tackling challenging cancers and blood disorders.

Founded in 2021 by scientific leaders Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen is pioneering advanced Chimeric Antigen Receptor T (CAR-T) cell therapies. The company's proprietary platform distinguishes itself by employing a dual-antigen targeting strategy. Unlike conventional CAR-T treatments that focus on a single cancer cell marker, Cellogen's method simultaneously targets two distinct markers. This sophisticated approach is designed to significantly enhance therapeutic efficacy and potentially reduce the likelihood of disease relapse, a critical challenge in current immunotherapy treatments.

The implications of this funding extend beyond mere operational expansion. The capital will be strategically deployed to propel Cellogen's CAR-T clinical programs through crucial developmental stages. Furthermore, it will support the expansion of its gene therapy pipeline and bolster its Good Manufacturing Practice (GMP)-compliant manufacturing facilities and regulatory affairs capabilities. The company is actively working towards initiating Phase I human clinical trials, with early collaborations already established with the esteemed CMC Vellore.

A key differentiator for Cellogen is its commitment to making these potentially life-saving treatments more accessible. Current CAR-T therapies often carry price tags ranging from $500,000 to $700,000. Cellogen, however, aims to offer its advanced treatments at a significantly lower cost, targeting a price point of $60,000 to $70,000. This aggressive pricing strategy could revolutionize patient access, particularly in emerging markets where the burden of cancer and blood disorders is substantial, but financial barriers are often prohibitive.

The company's innovative work has already garnered attention and validation from established industry players. Prior to this round, Natco Pharma, a prominent Indian pharmaceutical company, acquired a stake exceeding 5% for ₹15 crore. This earlier investment underscores the strong belief within the pharmaceutical sector regarding Cellogen's technological prowess and market potential. Beyond oncology, Cellogen is also developing early-stage programs targeting debilitating genetic blood disorders such as beta thalassemia and sickle cell disease, addressing significant unmet medical needs globally.

The broader market for cell and gene therapies is experiencing rapid growth, driven by advancements in genetic engineering and a deeper understanding of disease mechanisms. With an estimated market size projected to reach tens of billions of dollars in the coming years, companies like Cellogen, focusing on both innovation and affordability, are well-positioned to capture significant market share. This funding round from Kotak Alts provides Cellogen with the necessary resources to navigate the complex path from preclinical development to clinical application and eventual commercialization.